Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A CD57+CD8+ T cell subset links T cell cytotoxicity to fibrotic lung disease in systemic sclerosis.

The Journal of clinical investigation·2026

Same author

Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis.

Annals of the rheumatic diseases·2026

Same author

Criteria for defining and dating onset of organ system involvement in systemic sclerosis.

Journal of scleroderma and related disorders·2025

Same author

Telomere Length of Peripheral Blood Leukocytes Predicts Disease Severity and Worse Survival in Systemic Sclerosis.

Arthritis & rheumatology (Hoboken, N.J.)·2025

Same author

Cardiac involvement in systemic sclerosis: A critical review of knowledge gaps and opportunities.

Journal of scleroderma and related disorders·2025

Same author

Macrophages Contribute to Cardiac Fibrosis and Diastolic Dysfunction in Systemic Sclerosis.

JACC. Basic to translational science·2025

Search research articles

Related Experiment Videos

Immunotherapy of systemic sclerosis.

Rebecca Manno¹, Francesco Boin

¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, USA.

|November 25, 2010

Summary

Current scleroderma treatments focus on immunosuppression, with cyclophosphamide and mycophenolate mofetil being key options. Newer targeted therapies and stem cell transplantation show promise but require further research for safety and efficacy.

Area of Science:

Immunology
Rheumatology
Dermatology

Background:

Scleroderma is a complex autoimmune disease involving immune activation, vascular issues, and fibrosis.
Abnormal immune responses drive the disease's multisystem manifestations.

Purpose of the Study:

To review current immunomodulatory drug therapies for scleroderma.
To discuss the efficacy and limitations of existing and emerging treatments.

Main Methods:

Review of current literature on immunosuppressive and targeted therapies for scleroderma.
Analysis of clinical trial data and pilot studies for novel agents.

Main Results:

Cyclophosphamide remains a primary treatment for skin and lung involvement.

Related Experiment Videos

Mycophenolate mofetil shows potential as an alternative to cyclophosphamide.

Targeted T-cell and B-cell therapies, along with stem cell transplantation, offer promising outcomes but have associated toxicities.

Antifibrotic treatments and new biological agents are under investigation.

Conclusions:

Immunosuppression, particularly with cyclophosphamide, is central to scleroderma management.
Emerging targeted therapies and stem cell transplantation represent future directions, pending further safety and efficacy validation.
Ongoing research into antifibrotic and novel biological agents is crucial for advancing scleroderma treatment.